Posts Tagged Medical Center

When newborn mice are exposed to extra oxygen at birth — which causes their lungs to respond and develop similarly to those of preterm infants — they end up with far fewer of these cells once they reach adulthood and respond worse to the flu once fully grown.

Medical Center researchers have discovered that the loss of muscle stem cells, and not the loss of motor neurons, is the main driving force behind muscle decline in mice.

An intervention developed and tested by Medical Center psychiatrist J. Steven Lamberti and his team is the first of its kind in the country to prove its overall effectiveness and potential to reduce the high number of mentally ill individuals in U.S. prisons.

Researchers from the Center for RNA Biology have identified a new way to potentially slow the fast-growing cells that characterize all types of cancer.

The science behind harnessing the immune system to fight cancer is complicated, but a Medical Center laboratory discovered a simple, practical way to use light and optics to steer killer immune cells toward tumors.

Nearly one-fifth of the U.S. population will be 65 or older by the year 2030. To address this challenge, the University’s third annual d.health Summit will convene thought leaders across health care, finance, technology, and policy.

Medical Center researchers have discovered that a protein implicated in human longevity may also play a role in restoring hearing after noise exposure.

Physicians at the University of Rochester Medical Center have developed a new way to use 3D printing to fabricate artificial organs and human anatomy that mimics the real thing, even up to the point of bleeding when cut. These models are able to create highly realistic simulations for training and could soon be widely used to rehearse complex cases prior to surgery.

Individuals with diabetes have a high incidence of heart problems. A Medical Center study will determine if implantable defibrillators increase survival in this growing group of patients.

Medical Center researchers were instrumental in the U.S. Food and Drug Administration’s recent approval of SD-809 (deutetrabenazine) to treat Huntington’s disease.